Florbetaben PET imaging diagnoses amyloid beta plaques in Alzheimer's

A new scan may make it easier for doctors to accurately diagnose Alzheimer’s disease (AD). The results from the Phase III trial of florbetaben F18 injection, known by the trade name Neuraceq, were published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The injection material is a radiopharmaceutical that is used in imaging to “estimate the density of neuritic beta-amyloid plaques in the brains of adult patients with cognitive impairment.” Read more.

Tags: Brain PET Research

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap